Objective
To evaluate the correlation between metabolic syndrome (MetS) and its components on the incidence of colorectal cancer (CRC) based on data from Jinchang Cohort.
Methods
This is a large prospective cohort study. Between 2011 and 2020, a total of 43 516 individuals from Jinchang Cohort were included for this study. Hazard ratios (HRs) with 95% confidence intervals (CIs) for CRC according to MetS were calculated with the Cox proportional hazard models. The restricted cubic spine models with four knots were conducted to fit the dose-response relationships.
Results
MetS was associated with increased risk of CRC (n = 141; HR: 1.64, 95% CI: 1.15–2.33) after adjusting for confounding factors (age, sex, education level, family history of CRC, smoking index and alcohol index). Participants with hyperglycemia had a significantly higher risk of developing incident CRC (HR: 1.70; 95% CI: 1.19–2.43). The positive association between MetS and CRC was observed in males (HR: 1.76; 95% CI: 1.17–2.63), but not in females (HR: 1.24; 95% CI: 0.59–2.64). Furthermore, linear dose-response relationship was found between fasting plasma glucose (FPG) and CRC risk in males (P
overall < 0.05, P
non-linear = 0.35). When stratified by smoke and drink, MetS was found to increase the incidence of CRC only in the smoke (HR: 2.07, 95% CI: 1.35–3.18) and drink (HR: 2.93, 95% CI: 1.51–5.69) groups.
Conclusion
MetS was associated with a higher risk of CRC incidence. Hyperglycemia lended strong support to the role of MetS in new-onset CRC, especially in males. Other components of MetS were not found to be associated with increased risk of CRC.